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Abstract
Background: Much of the literature on panic disorder (PD)-bipolar disorder (BP) cormorbidity concerns BP-I. This
literature emphasizes the difficulties encountered in pharmacologic treatment and outcome when such comorbidity is
present. The present report explores these issues with respect to BP-II.
Methods: The sample comprised 326 outpatients (aged 34.5 ± 11.5 years old; 222 females) with Diagnostic and
Statistical Manual of Mental Disorders 3rd edn, revised (DSM-III-R) PD-agoraphobia; among them 52 subjects (16%) were
affected by lifetime comorbidity with BP-II. Patients were evaluated by means of the Structured Clinical Interview for
DSM-IV (SCID), the Panic-Agoraphobia Interview, and the Longitudinal Interview Follow-up Examination (Life-Up) and
treated according to routine clinical practice at the University of Pisa, Italy, for a period of 3 years. Clinical and course
features were compared between subjects with and without BP-II. All patients received the clinicians' choice of
antidepressants and, in the case of the subsample with BP-II, mood stabilizers (for example, valproate, lithium) were
among the mainstays of treatment.
Results:  In comparison to patients without bipolar comorbidity, those with BP-II showed a significantly greater
frequency of social phobia, obsessive-compulsive disorder, alcohol-related disorders, and separation anxiety during
childhood and adolescence. Regarding family history, a significantly greater frequency of PD and mood disorders was
present among the BP-II. No significant differences were observed in the long-term course of PD or agoraphobic
symptoms under pharmacological treatment or the likelihood of spontaneous pharmacological treatment interruptions.
Conclusion: Although the severity and outcome of panic-agoraphobic symptomatology appear to be similar in patients
with and without lifetime bipolar comorbidity, the higher number of concomitant disorders in our PD patients with BP-
II does indicate a greater complexity of the clinical picture in this naturalistic study. That such complexity does not seem
to translate into poorer response and outcome in those with comorbid soft bipolarity probably reflects the fact that we
had brought BP-II under control with mood stabilizers. We discuss the implications of our findings as further evidence
for the existence of a distinct anxious-bipolar diathesis.
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Background
Frequent comorbidity between panic disorder (PD) and
mood disorders has been widely reported in clinical [1-6]
and epidemiological studies [7-14]. Previously, most of
this research has been essentially limited to the co-occur-
rence of PD and unipolar disorders; recently, an increas-
ing attention has been paid to the co-occurrence of PD
and bipolar disorders (BP) [1,4,15-20].
Analyzing data from the Epidemiological Catchment Area
(ECA) study, Chen and Dilsaver [8] reported that the life-
time prevalence of PD was 20.8% in individuals with BP,
compared with 10% in those with unipolar major depres-
sion, and 0.8% in the general population. In the National
Comorbidity Survey [11], the reported risk of comorbid
PD is higher in bipolar than in unipolar disorder (odd
ratios respectively 11.0 vs 7.0). Similar data, including
high rates of PD-BP-II comorbidity, has emerged in epide-
miological studies conducted in European populations
[14,21,22].
In clinical studies 13% to 23% of adults with PD were
found to have comorbid BP [19,23-25]. Conversely, in BP
patients, rates of comorbid PD range from 10% to 80%
[1,8,16,20,24]. The majority of information on PD
comorbidity in patients with BP has been drawn from BP-
I samples [10,26-29]. Only a few studies focused on BP-II
disorder [18,30]. This relative neglect of PD-BP-II comor-
bidity is surprising, given the fact that BP-II seems to be
the most common bipolar phenotype in patients treated
for major depression and/or PD [18,31].
Several studies [32,33] have suggested that BP and PD
share common familial and genetic factors. In a follow-up
study, MacKinnon et al. [32] reported an unusually high
prevalence of PD in 57 families of probands with BP. A
linkage to markers on the long arm of chromosome 18
was observed only in families of BP probands with comor-
bid PD. In a recent study [33] on first-degree relatives (n =
966) of probands with bipolar I disorder (n = 192) and
schizoaffective disorder, bipolar type (n = 11), more than
90% of subjects with PD also had an affective disorder,
and PD was present in 17% of the relatives with recurrent
affective disorder compared with 3% of the relatives with-
out recurrent major affective disorder. These findings are
consistent with the hypothesis that familial BP increases
the risk for PD and this latter may be an index of genetic
heterogeneity in BP.
The association between PD and BP also raises important
questions from clinical and therapeutic points of view.
Most information in the literature is on patients with BP-
I and comorbid PD: they have more frequent mixed symp-
tomatology and suicidality, early onset panic attacks, and
significant increases in drug abuse and in physical mor-
bidity [1,17,20,34]. Moreover, history of panic attacks in
BP proved to be a significant correlate of non-remission;
type I BP patients with comorbid PD often require a
greater number of medications, either sequentially or in
combination, in order to achieve remission [17]. Less
information is available on patients with PD and comor-
bid BP-II; open reports indicated that they are more diffi-
cult to treat than patients without such comorbidity
[23,25,31].
In order to explore the clinical and therapeutic implica-
tions of comorbid BP-II, we analyzed data concerning 326
consecutive patients who sought medical help for PD and
who were treated according to routine clinical practice
and followed-up for a 3-year period.
Materials and methods
Study sample
The sample comprised 326 consecutive outpatients with
PD-agoraphobia evaluated and treated at the Psychiatric
Institute of the University of Pisa, Italy, from 1991 to
1995, and followed for a period of 3 years. The major aim
of the study was to describe the course and the evolution
PD-agoraphobia in a setting of routine clinical practice.
The study constitutes an offshoot from the Pisa-Memphis
(now San Diego) collaboration on the phenomenology
and outcome of affective and related disorders.
Inclusion criteria for the present protocol were (1) a prin-
cipal diagnosis of PD with or without agoraphobia
according to Diagnostic and Statistical Manual of Mental
Disorders 3rd edn, revised (DSM-III-R) criteria, (2)
absence of severe physical and laboratory abnormalities
and (3) absence of current psychotic disorders (last 6
months). Previous psychotic features during depressive
episodes or depressive mixed states did not represent
exclusion criteria. All patients gave informed consent for
their participation in the study.
All patients were evaluated by the senior psychiatrists on
the project (GP and CT) to ensure that admission criteria
were met. Presence of a current or past history of mood or
other anxiety disorders (lifetime comorbidity) was not
considered as exclusion criteria to ensure the selection of
patients that covered the full range of the clinical universe
applying for treatment.
The mean age of our sample at the time of admission into
the study was 34.5 (SD = 11.5, range = 18–73) and 222
(68.1%) were female. Mean age at onset was 29.3 (SD =
10.7, range = 6–64) for PD and 30.1 (SD = 9.2, range =
14–58) for agoraphobia. Agoraphobia was present in
92.6% (n = 302) of the sample.Annals of General Psychiatry 2008, 7:23 http://www.annals-general-psychiatry.com/content/7/1/23
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Methods
An intensive face-to-face interview that consisted of struc-
tured and semi-structured components was used to collect
data. The interview lasted approximately 1 h at baseline,
and 0.5 h for subsequent visits. The interviews were per-
formed by senior residents with extensive clinical experi-
ence in the diagnosis and treatment of anxiety disorders.
Each interviewer underwent a training program in the use
of the interview instruments that included direct observa-
tion of experienced interviewer, and inter-rater trials. The
interviewers were not involved in treatment decisions,
which were entrusted to an independent clinician.
At baseline patients were evaluated by means of the Struc-
tured Clinical Interview for Diagnosis (SCID) [35], the
Panic Disorder/Agoraphobia Interview [36,37] and the
Longitudinal Interview Follow-up Examination (Life-Up)
[38]. Life-Up has been designed to be administered every
6 months; however, as accuracy is duly enhanced by
shorter intervals, it can be administered more frequently
according to the specific design of a given study. In our
case, it was administered during the periodic visits at every
2 months or at shorter intervals, as dictated by clinical
necessity. Patients who interrupted follow-up assessment
were contacted at the end of the 3 years of follow-up and
evaluated by means of a semi-structured interview, widely
utilized in the World-Wide Upjohn Follow-up Study [39].
This particular interview lasted 30–40 min and was car-
ried out face to face or by phone.
High reliability for both principal (k = 0.96) and comor-
bid (kappa from 0.80 to 0.93) diagnoses have been docu-
mented in a subsample (n = 15).
Panic Disorder/Agoraphobia Interview
This instrument is subdivided into different sections
exploring: (1) demographic characteristics, based on the
Adult Demographic and Personal Inventory [40]; (2) fam-
ily history of anxiety, mood and other disorders in first
degree relatives, based on Winokur's approach as incorpo-
rated into the Family History version of the Research
Diagnostic Criteria [41]; (3) personal history of the
patient using the first panic attack as the primary anchor-
ing point. Once the period of the first panic attack was
described, the number of years preceding and following
this event was reviewed with particular focus on the symp-
tomatological characteristics of PD, the course of the ill-
ness and comorbidity with other mental disorders; and
(4) affective temperaments according to Akiskal and
Mallya [42] criteria and avoidant and dependent person-
ality disorders according to DSM-III-R criteria, the former
now shown to have good reliability and internal consist-
ency in the Temperament Evaluation of Memphis, Pisa,
Paris and San Diego, Interview version (TEMPS-I) [43],
and the latter based on the corresponding sections of the
SCID [44].
Life-Up
This is a semi-structured interview and rating system for
assessing the longitudinal course of psychiatric disorders
in sufficient detail to enable researchers to date individual
episodes of any psychiatric disorder and thus to provide
the basis for precise calculation of time to recovery, length
of ensuing wellness intervals, and time to subsequent
relapse or recurrence. The instrument [38] consists of dif-
ferent sections geared to assess psychopathological fea-
tures, obtain history for psychiatric treatment and
psychosocial functioning, as well as that for non-psychiat-
ric medical illness. Finally, the Life-Up provides a global
assessment scale according to which the overall health
and functioning of the patients are indicated. PD and ago-
raphobia severity is recorded week by week on a score
scale ranging from 1 to 6.
According to this instrument, 'remission' is defined as a
period of 8 weeks during which patients with PD have no
attacks, though sometimes they may feel on the verge of
an acute attack. 'Recurrence' is defined as a period of at
least 4 weeks during which patients have one or more
panic attacks per day, or a persistent fear of them. For ago-
raphobia, 'remission' is defined as the absence of avoid-
ance for a period of 8 weeks, while 'recurrence' defines a
period of at least 4 weeks, during which avoidance is
present.
Drop-out Interview
This instrument is specifically designed to explore symp-
toms, disability, help seeking and medications after the
end of the study and in the last year [39]. After the regis-
tration of the reasons of interruption, such as remission,
inefficacy of the treatment, side effects, distance to the
clinic, onset of other medical diseases, etc., the course of
the illness was investigated. In this way, remissions and
recurrences throughout the period from the interruption
of the study to the moment of the interview were
recorded. Moreover, drugs that had been taken during
that period were registered.
Treatment management
Clinicians involved in the treatment decisions and man-
agement were independent from the raters. Patients were
treated according to routine clinical practice with antide-
pressants. Most of them received imipramine (n = 127,
39%), clomipramine (n = 93, 28.5%) or paroxetine (n =
76, 23.3%). Only a few patients (n = 30, 9.2%) were
assigned to other medications, such as fluvoxamine,
fluoxetine, citalopram or trimipramine, when, according
to the individual physician's judgment, it was not possibleAnnals of General Psychiatry 2008, 7:23 http://www.annals-general-psychiatry.com/content/7/1/23
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to treat them with the former drugs, either because of
hypersensitivity or previous negative experiences.
In the first years of the study, tricyclic antidepressants
(TCAs) represented the best known antipanic agents and
for this reason they have been widely employed in our
patients. Subsequently, the acquisition of the antipanic
properties of paroxetine [45] has prompted the use of
these new compounds in the outpatients enrolled in the
follow-up study. Only since 1995 has paroxetine emerged
in our experience as a viable first line intervention drug for
PD-agoraphobia. Initially, paroxetine was prescribed to
patients judged less severe. Subsequently, paroxetine was
also prescribed to those subjects for whom TCAs were
contraindicated, as well as in those who had shown a jit-
teriness syndrome or supersensitivity to anticholinergic
side effects. The initial dose was for 10 mg of imipramine
or clomipramine and 10 mg of paroxetine. Dosage was
gradually increased (10 mg every 2 days for TCAs and 5
mg every 4 days for paroxetine) to a maximum of 300 mg
and 40–50 mg respectively. The treating clinician could
raise or lower the dose, depending upon the individual
patient's clinical state or side effects. After the first 4 weeks
of treatment and during each subsequent interval
assessed, most patients remained on nearly the same dose
of antidepressant. At the fourth week, the daily mean dos-
ages of imipramine, clomipramine and paroxetine were,
respectively, 132.6 ± 74.3 mg/day (range 30–250), 109.3
± 84.6 mg/day (range 40–300), and 28.7 ± 14.6 mg/day
(range 10–60). Superposable values were observed at the
beginning of the first remission (imipramine, 116 ± 79.8
mg/day, range 30–300; clomipramine, 126.2 ± 73.8 mg/
day, range 25–250; paroxetine, 30.6 ± 11.2 mg/day, range
10–50) and at the last evaluation (imipramine, 121.8 ±
81.2 mg/day, range 30–300; clomipramine, 115.9 ± 74.4
mg/day, range 25–250; paroxetine, 28.6 ± 10.2 mg/day,
range 10–50). No statistically significant differences in
daily mean dose of antidepressants were observed
between patients with or without bipolar II comorbidity.
At baseline, for those patients who were taking benzodi-
azepines (BDZ) a gradual tapering was scheduled. Subse-
quently, the administration of BDZ was allowed only
occasionally when absolutely unavoidable.
When comorbidity with BP-II was present, mood stabiliz-
ers such as valproate or lithium were prescribed. The latter
was based on clinicians' judgment, according to routine
clinical practice. All bipolar patients were deemed by the
investigators to have derived maximum benefit from the
treatment with mood stabilizers prior to receiving antide-
pressants. At the time the latter were started, PD/agora-
phobia was present at a clinical level in all subjects.
Statistics
Statistical comparisons between patients with PD (n =
274) and PD+BP-II (n = 52) were conducted by means of
analysis of variance (ANOVA) and chi-square analysis for
continuous and categorical variables, respectively. Kap-
lan-Maier survival analysis was utilized to define the rela-
tionship between PD course (length of periods free from
the illness and number of recurrences) and the presence of
comorbid BP-II.
Results
Of the 326 PD patients of our sample, 52 (16%) had
comorbid BP-II. At the time that treatment with antide-
pressants was started, none of them were suffering from
hypomanic episode, but a major depressive episode pre-
sented in 21 (40.4%) vs 91 (33.2%) subjects, respectively
in the group with and without bipolar II comorbidity (chi
square = 1.0; p = not significant (NS)).
Comparisons between bipolar patients and those without
BP-II showed similar results with respect to demographic
and clinical features, such as age, sex distribution, age at
onset, length of illness, presence of agoraphobia, person-
ality and temperamental features, as well as the severity
scores of PD and agoraphobia and Global Adjustment
Score (GAS) at baseline evaluation (Table 1).
Some statistically significant differences were observed as
regards the lifetime presence of other comorbid mental
disorders: patients with BP-II showed a significantly
greater frequency of social phobia and obsessive-compul-
sive disorder, as well as alcohol-related disorders, in com-
parison with patients without bipolar comorbidity.
Bipolar patients were also significantly more likely to
report a positive history of separation anxiety during
childhood and adolescence. The presence of comorbid
generalized anxiety disorder was not significantly differ-
ent between the two groups (Table 1).
As regards family history, a significantly greater frequency
of PD-agoraphobia was present in the group with BP, as
well as a greater familial load for mood disorders. Family
history of substance-related disorders (including alcohol)
was similar in the two groups (Table 1).
No significant differences were observed in the efficacy of
the various drug treatments (Table 2). Likewise, the com-
parison between bipolar and non-bipolar PD patients
showed that the presence of BP-II did not influence the
likelihood of staying in the follow-up or interrupting the
pharmacological treatment for various reasons, such as
remission or ineffectiveness (Table 3). Moreover, the pres-
ence of comorbidity with BP-II did not appear to have sig-
nificant effects on the long-term course of either PD or
agoraphobia. Kaplan-Maier survival analysis showed thatAnnals of General Psychiatry 2008, 7:23 http://www.annals-general-psychiatry.com/content/7/1/23
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time of remission both for PD (Mantel-Cox chi-square =
0.018, df = 1, p = NS) and agoraphobia (Mantel-Cox chi-
square = 0.002, df = 1, p = NS) was similar in the two
groups. Also similar was the time of relapse for PD (Man-
tel-Cox chi-square = 0.963, df = 1, p = NS) and for agora-
phobia (Mantel-Cox chi-square = 0.969, df = 1, p = NS).
Additionally, no difference between patients with and
without comorbid BP-II was observed in the mean dura-
tion of total remission and relapse periods (Table 4).
Table 1: Clinical characteristics of panic disorder patients with and without comorbid bipolar disorder
PD (n = 274) PD+BD (n = 52) F/chi-square p Value
Age, mean (SD) 36.7 (11.5) 35.1 (11.6) -0.9 NS
Sex, female, n (%) 191 (69.7) 31 (59.6) 2.0 NS
Agoraphobia, n (%) 219 (79.9) 44 (84.6) 0.06 NS
First degree family history, n (%):
Mood disorders 83 (30.3) 23 (44.2) 3.9 0.05
Substance abuse 10 (3.7) 3 (5.8) 0.5 NS
Panic-agoraphobic disorder 110 (40.1) 33 (63.5) 9.6 0.002
Age at onset, mean (SD) 29.9 (10.5) 26.0 (11.0) -2.5 NS
Length of illness in months, mean (SD) 87.2 (128.4) 117.4 (159.4) 1.5 NS
Life-up scores at baseline, mean (SD):
Panic disorder 3.4 (1.0) 3.2 (0.8) -0.9 NS
Agoraphobia 3.0 (1.2) 3.0 (1.0) 0.2 NS
General adjustment (GAS) 69.8 (11.1) 68.3 (9.8) -0.9 NS
Lifetime comorbidity, n (%):
Major depression 91 (33.2) -
Generalized anxiety 46 (16.8) 12 (23.1) 1.2 NS
Social phobia 21 (7.7) 9 (17.3) 4.9 0.03
Obsessive-compulsive 20 (7.3) 11 (21.1) 9.7 0.002.
Alcohol-related disorders 16 (5.8) 9 (17.3) 8.1 0.004.
Separation anxiety 85 (31.0) 24 (46.1) 4.5 0.03
Personality disorders, n (%):
Avoidant 64 (23.4) 16 (30.8) 1.3 NS
Dependent 37 (13.5) 7 (13.5) 0.000 NS
BP, bipolar disorder; GAS, Global Adjustment Score; NS, not significant; PD, panic disorder.Annals of General Psychiatry 2008, 7:23 http://www.annals-general-psychiatry.com/content/7/1/23
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Discussion
This study evaluates the prevalence of BP-II lifetime
comorbidity and its consequences on clinical features and
treatment response in a large group of PD outpatients fol-
lowed in a naturalistic setting of routine pharmacological
treatment. To our knowledge, this is the first study that
has dealt with the impact of BP-II on the course of PD in
patients selected on the basis of PD-agoraphobia as a prin-
cipal diagnosis. The 16% prevalence rate of comorbid BP-
II in our patients is consistent with those observed in
other clinical samples selected with similar criteria
[19,23,25]. The findings from different psychiatric centers
in both Europe and the US go against a common percep-
tion that the relationship between anxiety and mood dis-
orders is largely limited to unipolar depression and
dysthymia. The importance of screening all PD-agorapho-
bic patients for past hypomania should be emphasized.
We did not find any significant effect of BP-II comorbidity
on the clinical features of PD, including those related to
the severity of the disease such as age at onset of panic
attacks, baseline severity of PD-agoraphobia, general
adjustment scores, and length of illness. Moreover, such
comorbidity does not appear to have significant effects on
the long-term outcome of the PD-agoraphobia, as indi-
cated by the mean duration of the remission or the relapse
periods. Even the responses to pharmacological therapy
and the patients' adherence to long-term drug treatment
do not appear to be significantly influenced by the pres-
ence of BP-II.
Previous clinical studies on BP-I patients with comorbid
PD showed more severe symptomatology with early onset
of panic attacks. Moreover, they were more difficult to
treat than BP subjects without comorbid PD
[8,17,23,34,46]. This discrepancy might be accounted for
by the different criteria used for the selection of the sam-
ple. In fact, whereas other clinical studies typically
described inpatients with mania and/or mixed mania
with concomitant PD, the present study focused on PD
outpatients with comorbid BP-II. This choice was justified
by growing evidence that limiting the diagnosis of the
bipolar spectrum disorders to the classical type I form is
too restrictive and severely underestimates the presence
and impact of the bipolar disease [2,47,48].
Moreover, the present study aimed to investigate the pres-
ence and the implications of bipolar comorbidity on PD-
agoraphobia in a naturalistic setting of routine clinical
practice, and BP-II is the most common form of bipolarity
in such a setting [49]. Broadening the inclusion of bipo-
larity to less severe, softer and more prevalent forms might
account for the milder effects of bipolar comorbidity on
the severity and course of PD-agoraphobia that were
found in our sample.
BP-II comorbidity, nonetheless, appears to influence the
pattern of lifetime clinical features in PD patients, espe-
cially with regard to the presence of alcohol and substance
use and other concomitant anxiety disorders, such as
social phobia and obsessive-compulsive disorders. The
coexistence of multiple anxiety and substance-related dis-
orders with bipolarity has been reported in previous clin-
ical studies [48,50,51].
Although the severity and the outcome of panic-agora-
phobic symptomatology seem to be similar in patients
with and without BP-II comorbidity, the higher number
Table 2: Drug treatments of panic disorder patients with and without comorbid bipolar disorder
PD n (%) PD+BD n (%) Chi-square p Value
Imipramine 105 (38.3) 22 (42.3)
Clomipramine 81 (29.6) 12 (23.1)
Paroxetine 60 (21.9) 16 (30.8)
Other 28 (10.2) 2 (3.8) 4.2 NS
BP, bipolar disorder; NS, not significant; PD, panic disorder.
Table 3: Different reasons of treatment interruption in PD patients with and without comorbid bipolar disorder
PD n (%) PD+BD n (%) Chi-square p Value
In treatment 122 (44.5) 25 (48.1)
Remission 56 (20.4) 10 (19.2)
Ineffectiveness 45 (16.4) 7 (13.5)
Lost to follow-up 41 (15.0) 7 (13.5)
Other reasons 10 (3.6) 3 (5.8) 0.9 NS
BP, bipolar disorder; NS, not significant; PD, panic disorder.Annals of General Psychiatry 2008, 7:23 http://www.annals-general-psychiatry.com/content/7/1/23
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of concomitant disorders in our PD patients with BP-II
indicated a greater complexity of the overall clinical pic-
ture. The latter might explain the treatment difficulties
reported in open clinical observations [23,25,31]. The fact
that our center specializes in BP-II may have led to opti-
mal or reasonable stabilization of the bipolar component
of the comorbidity in the present sample.
Another interesting finding is the presence of higher rates
of childhood separation anxiety among subjects with
comorbid BP-II in comparison with other PD patients.
Anxious bipolarity thus appears to be related to a more
intense vulnerability for early onset phobic-anxious man-
ifestations, indicating that clinical complexity in these
patients extends to childhood precursors of PD-agorapho-
bia [52].
The pattern of complex relationships among PD and
mood disorders would require better-designed prospec-
tive observations. Nonetheless, the validity of the phe-
nomenon of anxious-bipolar comorbidity should no
longer be in doubt. This relationship is further suggested
by our finding of a stronger load of PD-agoraphobia
among the first-degree relatives of PD subjects with BP-II.
Previous reports from family studies have also reported
high prevalence rates of PD in families with a high load of
bipolar disorder [32,33].
Our findings are consistent with the hypothesis that, at
least in a significant minority of cases, PD and BP-II may
share common familial and genetic factors, and these fac-
tors may influence the earliest manifestations of the
panic-agoraphobic syndrome and the complexity of the
longitudinal clinical picture. By contrast, bipolar comor-
bidity does not seem to have significant effects on the
severity of the core symptomatological features, as well as
the clinical course or response to treatments of the full-
blown panic-agoraphobic syndrome that, hypothetically,
appears to be shaped by other factors, possibly distinct
and unrelated to BP comorbidity.
Other attractive theoretical possibilities must be consid-
ered too. Indeed, the recognition of bipolar comorbidity
in PD patients has relevant theoretical and practical impli-
cations. In hypothesizing a putative common substrate,
the fact that not only depression but also (hypo)mania
and mixed states frequently coexist with anxious-phobic
symptomatology should be taken into account.
Hypomanic switches on antidepressants or alcohol repre-
sent frequent coexisting mood states in the longitudinal
history of many PD patients [1,4,18,53]. In a more theo-
retical vein, we submit that the foregoing considerations
challenge the view that anxiety and bipolar spectrum dis-
orders are completely independent syndromes, and they
stress the advantage of diagnosing such comorbidity from
the psychopathological, clinical, and public health per-
spectives. To recapitulate what we have advanced in the
present work, the co-occurrence of bipolar and panic-ago-
raphobic spectra suggests that a distinct anxious-bipolar
diathesis does exist. Most panic-agoraphobic disorders are
probably unrelated to such an entity. By contrast, a sub-
stantial proportion of BP-II might belong to the joint anx-
ious-bipolar diathesis, possibly part of an even broader
spectrum of psychopathology [48].
One important caveat of this study is that we focused
herein on the pharmacologic treatment of the PD-agora-
phobia in otherwise mood stabilized BP-II. The optimum
treatment of BP-II in the presence of panic-agoraphobic
disorders, often also comorbid with social phobia, repre-
sents a therapeutic challenge to clinicians. Such panic-
agoraphobia comorbidity has been described with BP-I,
with delayed and poorer naturalization outcome for the
bipolar disorder [54]. In our clinical experience, the same
is equally true for BP-II, unless it is stabilized before insti-
tuting pharmacologic treatments for the anxious comor-
bidity. This topic will be the subject of a subsequent
manuscript by our group.
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Table 4: Long term course in PD patients with and without comorbid bipolar disorder
PD, mean (SD) PD+BD, mean (SD) F/chi-square p Value
PD:
Remission length, months 72.2 (40.9) 73.4 (39.6) 0.2 NS
Relapse length, months 26.0 (22.2) 28.4 (25.6) 0.5 NS
Agoraphobia:
Remission length, months 72.5 (42.6) 78.1 (40.6) 0.8 NS
Relapse length, months 29.3 (23.8) 32.0 (25.9) 0.4 NS
BP, bipolar disorder; NS, not significant; PD, panic disorder.Annals of General Psychiatry 2008, 7:23 http://www.annals-general-psychiatry.com/content/7/1/23
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